| Vaccine | Antigens | Manufacturer | PI Date |
|---|---|---|---|
| ERVEBO | Ebola Zaire | Merck Sharp & Dohme LLC | 2023-07 |
| FluMist | Influenza (2025-26 Formula) | AstraZeneca | 2025-08 |
| NUVAXOVID | COVID-19, Adjuvanted | Novavax, Inc. | 2025-07 |
| Fluarix | Influenza (2025-26 Formula) | GlaxoSmithKline | 2025-07 |
| Flublok | Influenza (2025-26 Formula) | Sanofi Pasteur | 2025-07 |
| FluLaval | Influenza (2025-26 Formula) | ID Biomedical | 2025-07 |
| Fluzone High-Dose | Influenza (2025-265 Formula) | Sanofi Pasteur | 2025-07 |
| Shingrix | Varicella Zoster | GlaxoSmithKline | 2025-07 |
| Comirnaty | COVID-19, mRNA | BioNTech Manufacturing GmbH | 2025-06 |
| MNEXSPIKE | COVID-19, mRNA | ModernaTx, Inc | 2025-06 |
| Abrysvo | Respiratory Syncytial Virus | Wyeth/Pfizer | 2025-06 |
| mResvia | Respiratory Syncytial Virus | ModernaTx, Inc | 2025-06 |
| Cyfendux | Anthrax Vaccine Adsorbed | Emergent BioSolutions | 2025-05 |
| Arexvy | Respiratory Syncytial Virus | GlaxoSmithKline | 2025-05 |
| Gardasil | Human Papillomavirus (Types 6, 11, 16, and 18) | Merck | 2025-04 |
| YF-VAX | Yellow Fever | Sanofi Pasteur | 2025-04 |
| Pentacel | Diphtheria, Tetanus, Pertussis, Poliomyelitis, and Haemophilus influenzae type b | Sanofi Pasteur | 2025-03 |
| ActHIB | Haemophilus influenzae type b (PRP-T) | Sanofi Pasteur | 2025-03 |
| Gardasil 9 | Human Papillomavirus (Types 6, 11, 16, and 18) | Merck | 2025-03 |
| Menveo | Meningococcal Groups A,C,Y and W-135 | GlaxoSmithKline | 2025-03 |
| IPOL | Polio (inactivated) | Sanofi Pasteur | 2025-03 |
| Vaxchora | Cholera | Bavarian Nordic A/S | 2025-02 |
| PENMENVY | Meningococcal Groups A, B, C, W and Y | GSK | 2025-02 |
| RabAvert | Rabies (PCEC) | GlaxoSmithKline | 2025-02 |
| Hiberix | Haemophilus b Conjugate Vaccine | GlaxoSmithKline | 2025-01 |
| Havrix | Hepatitis A | GlaxoSmithKline | 2024-12 |
| Infanrix | Diphtheria, Tetanus, (acellular) Pertussis | GlaxoSmithKline | 2024-12 |
| KINRIX | Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus | GlaxoSmithKline | 2024-11 |
| Engerix-B | Hepatitis B | GlaxoSmithKline | 2024-11 |
| M-M-R II | Measles, Mumps, Rubella (live) | Merck | 2024-11 |
| PENBRAYA | Meningococcal Groups A, B, C, W and Y | Pfizer | 2024-11 |
| Boostrix | Tetanus toxoid, reduced Diphtheria Toxoid, Acellular Pertussis Vaccine Adsorbed | GlaxoSmithKline | 2024-11 |
| ACAM2000 | Smallpox (Vaccinia) | Emergent Product Development | 2024-10 |
| SPIKEVAX | COVID-19, mRNA | ModernaTx, Inc | 2024-09 |
| Heplisav-B | Hepatitis B | Dynavax | 2024-09 |
| MenQuadfi | Meningococcal Groups A, C, Y, and W | Sanofi Pasteur | 2024-09 |
| Bexsero | Meningococcal Group B | GlaxoSmithKline | 2024-08 |
| Afluria | Influenza (2024-25 Formula) | Seqirus | 2024-07 |
| Fluzone | Influenza (2024-25 Formula) | Sanofi Pasteur | 2024-07 |
| Fluad | Influenza (2024-25 Formula) | Seqirus | 2024-07 |
| Flucelvax | Influenza (2024-25 Formula) | Seqirus | 2024-07 |
| Trumenba | Meningococcal Group B | Wyeth/Pfizer | 2024-06 |
| Capvaxive | Pneumococcal 21-valent Conjugate Vaccine | Merck | 2024-06 |
| Adacel | Tetanus toxoid, reduced Diphtheria Toxoid, Acellular Pertussis Vaccine Adsorbed | Sanofi Pasteur | 2024-06 |
| Pediarix | Diphtheria, Tetanus, Pertussis, Hepatitis B and Poliovirus | GlaxoSmithKline | 2024-05 |
| Twinrix | Hepatitis A and B | GlaxoSmithKline | 2024-05 |
| Vaxneuvance | Pneumococcal 15-valent Conjugate Vaccine | Merck | 2024-05 |
| Priorix | Measles, Mumps, Rubella (live) | GlaxoSmithKline | 2024-04 |
| Imovax Rabies | Rabies Vaccine (HDCV) | Sanofi Pasteur | 2024-04 |
| Tenivac | Tetanus and Diptheria Toxoids Adsorbed | Sanofi Pasteur | 2024-04 |
| Rotarix | Rotavirus Vaccine, Live, Oral, | GlaxoSmithKline | 2024-01 |
| ProQuad | Measles, Mumps, Rubella and Varicella | Merck | 2023-08 |
| Varivax | Varicella (live) | Merck | 2023-08 |
| TICOVAC | Tick-bourne Encephalitis | Pfizer Ireland Pharmaceuticals | 2023-07 |
| PedvaxHIB | Haemophilus influenzae type b (PRP-OMP) | Merck | 2023-04 |
| Vaqta | Hepatitis A (inactivated) | Merck | 2023-04 |
| Recombivax HB | Hepatitis B (recombinant) | Merck | 2023-04 |
| Pneumovax 23 | Pneumococcal (polysaccharide) | Merck | 2023-04 |
| Prevnar 20 | Pneumococcal 20-valent Conjugate Vaccine | Wyeth/Pfizer | 2023-04 |
| RotaTeq | Rotavirus Vaccine, Live, Oral, Pentavalent | Merck | 2023-04 |
| JYNNEOS | Smallpox and Mpox | Bavarian Nordic A/S | 2023-03 |
| DENGVAXIA | Dengue | Sanofi Pasteur | 2023 |
| Vaxelis | Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine | Merck/Sanofi Pasteur | 2022-10 |
| BCG Vaccine | Bacillus of Calmette and Guerin (BCG) | Merck | 2022-08 |
| Quadracel | Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus | Sanofi Pasteur | 2022-07 |
| Daptacel | Diphtheria, Tetanus, (acellular) Pertussis | Sanofi Pasteur | 2022-07 |
| PREHEVBRIO | Hepatitis B (recombinant) | VBI Vaccines (Delaware) Inc. | 2021-12 |
| Imogam Rabies-HT | Rabies Immune Globulin | Sanofi Pasteur | 2020-12 |
| Vivotif | Typhoid | Crucell | 2020-09 |
| Typhim Vi | Typhoid | Sanofi Pasteur | 2020-03 |
| Menactra | Meningococcal Groups A, C, Y, and W-135 Conjugate | Sanofi Pasteur | 2019-07 |
| Prevnar 13 | Pneumococcal 13-valent Conjugate Vaccine | Wyeth/Pfizer | 2019-07 |
| DT | Diphtheria and Tetanus Toxoids | Sanofi Pasteur | 2019-03 |
| Zostavax | Varicella Zoster | Merck | 2019-01 |
| Ixiaro | Japanese Encephalitis | Valneva | 2018-09 |
| TDVAX | Tetanus and Diphtheria Toxoids Adsorbed | Mass Biol Labs | 2018-09 |
| BioThrax | Anthrax Vaccine Adsorbed | Emergent BioSolutions | 2015-11 |
Institute for Vaccine Safety
Johns Hopkins Bloomberg School of Public Health
615 N Wolfe Street
Baltimore, MD 21205
USA
© 2025 Institute for Vaccine Safety
This website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Member since 2006